)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
PMV Pharmaceuticals
PMV Pharmaceuticals (PMVP) investor relations material
PMV Pharmaceuticals TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen 46th Annual Health Care Conference summary2 Mar, 2026
Key clinical insights
Lead candidate rezatapopt targets the TP53 Y220C mutation, previously considered undruggable, and shows promising efficacy in heavily pretreated cancer patients.
Phase 2 interim data show a 34% overall response rate (ORR) across all cohorts and a 46% ORR in ovarian cancer, with a median duration of response of 8 months in ovarian cancer.
Responses are consistent across subgroups, including platinum-resistant and refractory ovarian cancer, with rapid median time to response of 1.3 months.
Safety profile is favorable, with most adverse events being grade 1 or 2 and manageable; food administration has reduced GI side effects.
ctDNA analysis shows a 91% reduction in TP53 Y220C variant allele frequency, supporting on-target activity.
Regulatory and commercialization strategy
NDA submission for platinum-resistant/refractory ovarian cancer is planned for Q1 2027, with a potential US launch by end of 2027 and pursuit of accelerated approval.
Ongoing engagement with FDA has been supportive; further regulatory discussions and data updates are expected in H2 2024.
Commercialization may be pursued independently or via partnership, with a model similar to other recent biotech launches in ovarian cancer.
Patient identification is facilitated by broad NGS panel coverage and high testing rates in ovarian cancer; no significant barriers to adoption are anticipated.
US market potential is estimated at $350M–$420M, with global potential up to $630M for second-line plus ovarian cancer.
Expansion and future development
Label expansion beyond ovarian cancer is planned, with ongoing studies in endometrial, breast, and other solid tumors.
Investigator-initiated studies are underway in AML/MDS in partnership with MD Anderson, with future plans for combination therapies in both hematologic and solid tumors.
Preclinical data support combination with bevacizumab, and future combinations with pan-KRAS inhibitors and standard-of-care agents are being explored.
Enrollment is global and balanced between US and ex-US sites, with 70 sites activated and 120 patients targeted in the ovarian cancer cohort.
Educational efforts focus on linking TP53 mutation detection to therapeutic action, leveraging established NGS testing practices.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next PMV Pharmaceuticals earnings date
Q4 202513 Mar, 2026
PMV Pharmaceuticals
Next PMV Pharmaceuticals earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
PMV Pharmaceuticals Inc. is a U.S.-based biotechnology company focused on the discovery and development of targeted therapies for cancer. The company specializes in precision oncology, aiming to create treatments that address specific genetic mutations in cancer cells. Its work spans early-stage drug discovery through clinical development. The company is headquartered in Princeton, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage